Biocon Limited released Monitoring Agency Reports confirming zero deviation in utilizing ₹8,650 Crore raised via QIPs. The Audit Committee reviewed these reports on May 07, 2026.
Biocon Limited's Board will meet on May 07, 2026, to consider a preferential allotment of equity shares. This issuance is intended to fund the acquisition of equity shares in its material subsidiary, Biocon Biologics Limited, for consideration other than cash. The transaction is subject to shareholder approval via postal ballot.
